3,3-二乙基-2-吡咯烷酮 | 175698-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3,3-二乙基-2-吡咯烷酮
• 英文名称: 3,3-diethylpyrrolidin-2-one
• CAS: 175698-05-2
• 化学式: C₈H₁₅NO
• mdl: MFCD07784501
• 分子量: 141.213
• InChiKey: WYPUMACPRYGQOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22

反应信息

• 作为反应物：
  描述：

  4-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine 、 3,3-二乙基-2-吡咯烷酮 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 盐酸 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 1.58h， 以76 mg的产率得到3,3-diethyl-1-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyrrolidin-2-one hydrochloride
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的那样，或其盐。

  公开号：

  EP2832734A1
• 作为产物：
  描述：

  2-乙基丁酸乙酯 在 sodium tetrahydroborate 、 cobalt(II) chloride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 79.0h， 生成 3,3-二乙基-2-吡咯烷酮
  参考文献：
  名称：

  3,3-Dialkyl- and 3-Alkyl-3-Benzyl-Substituted 2-Pyrrolidinones:  A New Class of Anticonvulsant Agents

  摘要：

  A series of 3,3-dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones (lactams) have been prepared and evaluated for their anticonvulsant activities. In the pentylenetetrazole mouse seizure model, 3,3-diethyl lactam 7c and 3-benzyl-3-ethyl lactam 7j are the most effective anticonvulsants (ED(50) = 46 and 42 mg/kg, respectively) and have protective index (PI = TD50/ED(50)) values of 5.65 and 3.00, respectively. These protective index values compare favorably to those of the clinically used antiepileptic drugs ethosuximide (ED(50) = 161 mg/kg), phenobarbital (ED(50) = 22 mg/kg), and valproic acid (ED(50) = 133 mg/kg), which have PI values of 2.35, 4.00, and 2.12, respectively. The benzyl compounds [3-substituents are Bn, H (7h); Bn, Me (7i); and Bn, Et (7j)] are also very effective anticonvulsants against seizures induced by maximal electroshock (ED(50) = 41, 55, and 74 mg/kg, respectively) and have PI values of 3.51, 3.04, and 1.70, respectively. The corresponding PI values for phenobarbital and valproic acid are 1.37 and 5.18, respectively. As a class of anticonvulsants, the 3,3-disubstituted 2-pyrrolidinones have a broad spectrum of action and may be useful for the treatment of human epilepsies.

  DOI：

  10.1021/jm9600196

文献信息

• N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20200071302A1

  公开（公告）日：2020-03-05

  An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

  本申请公开了具有结构式（I）的N-(azaaryl)cyclolactam-1-羧酰胺衍生物，其制备方法及用途。每个取代基在规范和权利要求中有定义。本申请中的化合物系列可广泛应用于制备用于治疗癌症、肿瘤、自身免疫疾病、代谢性疾病或转移性疾病的药物，特别适用于治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、胶质母细胞瘤、多发性骨髓瘤、代谢性疾病、神经退行性疾病、原发肿瘤部位转移或骨转移癌症，并有望开发成为新一代CSF-1R抑制剂药物。
• Anticonvulsant and anxiolytic lactam and thiolactam derivatives
  申请人：Washington University

  公开号：US05776959A1

  公开（公告）日：1998-07-07

  This invention relates to lactam and thiolactam derivatives having useful anticonvulsant and anxiolytic activity, pharmaceutical compositions containing these compounds and therapeutic applications using such compositions.

  这项发明涉及具有有用的抗抽搐和抗焦虑活性的内酰胺和硫内酰胺衍生物，含有这些化合物的药物组合物以及使用这些组合物的治疗应用。
• Lactam and thiolactam derivatives as anesthetic and conscious sedation agents
  申请人：——

  公开号：US20030078283A1

  公开（公告）日：2003-04-24

  This invention relates to lactam and thiolactam derivatives having useful anesthetic and conscious sedation activity. Particularly useful compounds include the diethyl lactams such as 3,3-diethyl-2-pyrrolidinone. Methods for using these compounds and pharmaceutical compositions containing these compounds are provided.

  本发明涉及具有有用的麻醉和意识镇静活性的内酰胺和硫内酰胺衍生物。特别有用的化合物包括二乙基内酰胺，例如3,3-二乙基-2-吡咯酮。提供了使用这些化合物的方法和含有这些化合物的制药组合物。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US09187453B2

  公开（公告）日：2015-11-17

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿性关节炎、炎症性肠病、干燥综合征、Behcet病、多发性硬化症、系统性红斑狼疮等）的药剂，其具有优越的Tyk2抑制作用。本发明涉及一种由式子表示的化合物，其中每个符号如规范中所定义，或其盐。
• N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US11149021B2

  公开（公告）日：2021-10-19

  An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

  本申请公开了一种具有式(I)结构的 N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和用途。各取代基在说明书和权利要求中均有定义。本申请的系列化合物可广泛应用于制备治疗癌症、肿瘤、自身免疫性疾病、代谢性疾病或转移性疾病的药物，特别是用于治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、胶质母细胞瘤、多发性骨髓瘤、代谢性疾病、神经退行性疾病、原发肿瘤部位转移或骨转移癌，有望开发成新一代CSF-1R抑制剂药物。